PMID- 29891331
OWN - NLM
STAT- MEDLINE
DCOM- 20190523
LR  - 20190523
IS  - 2352-3840 (Electronic)
IS  - 1499-2671 (Linking)
VI  - 43
IP  - 1
DP  - 2019 Feb
TI  - Serum Brain-Derived Neurotrophic Factor is Related to Platelet Reactivity and 
      Metformin Treatment in Adult Patients With Type 2 Diabetes Mellitus.
PG  - 19-26
LID - S1499-2671(17)30734-7 [pii]
LID - 10.1016/j.jcjd.2018.01.014 [doi]
AB  - OBJECTIVES: The aim of this study was to investigate the association of serum 
      brain-derived neurotrophic factor (BDNF) levels with platelet reactivity and 
      antidiabetes treatment, as well as serum adipocytokine concentrations. METHODS: 
      This observational, open-label study enrolled 149 patients. Serum BDNF, 
      hematologic, biochemical parameters and platelet reactivity were measured. Blood 
      samples were taken after the last acetylsalicylic acid dose. RESULTS: Patients 
      with high BDNF levels were younger (65.60+/-8.956 vs. 68.59+/-8.516) and smoked 
      cigarettes more frequently (14.6% vs. 4.1%); they were more commonly being 
      treated by metformin (77.3% vs. 54%); had higher platelet counts (245.81+/-68.85 
      10(3)/mm(3) vs. 206.61+/-44.48 10(3)/mm(3)); had shorter collagen-adenosine 
      diphosphate closure time (CADP-CT) values (104.88+/-69.73 s vs. 140.93+/-86.63 s); 
      had higher triglyceride concentrations (140.73+/-67.5 vs. 121.76+/-60.49) and had 
      higher concentrations of serum thromboxane B2 (0.938+/-1.59 vs. 0.364+/-0.76). In 
      univariate linear regression analyses, predictive factors for serum BDNF levels 
      above the median were metformin treatment, current smoking, platelet count, 
      triglyceride concentration, total cholesterol concentration and CADP-CT >74 s. In 
      multivariate backward stepwise analysis CADP-CT >141 s; adiponectin concentration 
      >4.22 microg/mL; total cholesterol and low-density lipoprotein levels were 
      independently associated with serum BDNF levels above the median. CONCLUSIONS: 
      Our results suggest that BDNF may be associated with lipid metabolism and that 
      increased production of BDNF may be related to metformin treatment. Moreover, we 
      showed an association between BDNF levels and platelet reactivity; we found that 
      serum BDNF levels in patients with type 2 diabetes who had high platelet 
      reactivity were higher than in subjects with normal platelet reactivity despite 
      antiplatelet therapy.
CI  - Copyright (c) 2018 Diabetes Canada. Published by Elsevier Inc. All rights reserved.
FAU - Eyileten, Ceren
AU  - Eyileten C
AD  - Department of Experimental and Clinical Pharmacology, Medical University of 
      Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland.
FAU - Mirowska-Guzel, Dagmara
AU  - Mirowska-Guzel D
AD  - Department of Experimental and Clinical Pharmacology, Medical University of 
      Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland. 
      Electronic address: dmirowska@wum.edu.pl.
FAU - Milanowski, Lukasz
AU  - Milanowski L
AD  - Department of Experimental and Clinical Pharmacology, Medical University of 
      Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland.
FAU - Zaremba, Malgorzata
AU  - Zaremba M
AD  - Department of Experimental and Clinical Pharmacology, Medical University of 
      Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland.
FAU - Rosiak, Marek
AU  - Rosiak M
AD  - Department of Experimental and Clinical Pharmacology, Medical University of 
      Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland.
FAU - Cudna, Agnieszka
AU  - Cudna A
AD  - Department of Experimental and Clinical Pharmacology, Medical University of 
      Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland.
FAU - Kaplon-Cieslicka, Agnieszka
AU  - Kaplon-Cieslicka A
AD  - Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
FAU - Opolski, Grzegorz
AU  - Opolski G
AD  - Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
FAU - Filipiak, Krzysztof J
AU  - Filipiak KJ
AD  - Department of Cardiology, Medical University of Warsaw, Warsaw, Poland.
FAU - Malek, Lukasz
AU  - Malek L
AD  - Faculty of Rehabilitation, University of Physical Education, Warsaw, Poland.
FAU - Postula, Marek
AU  - Postula M
AD  - Department of Experimental and Clinical Pharmacology, Medical University of 
      Warsaw, Center for Preclinical Research and Technology CEPT, Warsaw, Poland.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
PT  - Randomized Controlled Trial
DEP - 20180203
PL  - Canada
TA  - Can J Diabetes
JT  - Canadian journal of diabetes
JID - 101148810
RN  - 0 (Biomarkers)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - 9100L32L2N (Metformin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aspirin/pharmacology/therapeutic use
MH  - Biomarkers/blood
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Diabetes Mellitus, Type 2/*blood/*drug therapy
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Male
MH  - Metformin/pharmacology/*therapeutic use
MH  - Middle Aged
MH  - Platelet Activation/*drug effects/physiology
MH  - Platelet Aggregation Inhibitors/pharmacology/therapeutic use
MH  - Prospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - adiponectin
OT  - adiponectine
OT  - aspirin
OT  - aspirine
OT  - diabetes mellitus
OT  - diabete sucre
OT  - metformin
OT  - metformine
OT  - plaquette
OT  - platelet
EDAT- 2018/06/13 06:00
MHDA- 2019/05/24 06:00
CRDT- 2018/06/13 06:00
PHST- 2017/09/02 00:00 [received]
PHST- 2018/01/31 00:00 [accepted]
PHST- 2018/06/13 06:00 [pubmed]
PHST- 2019/05/24 06:00 [medline]
PHST- 2018/06/13 06:00 [entrez]
AID - S1499-2671(17)30734-7 [pii]
AID - 10.1016/j.jcjd.2018.01.014 [doi]
PST - ppublish
SO  - Can J Diabetes. 2019 Feb;43(1):19-26. doi: 10.1016/j.jcjd.2018.01.014. Epub 2018 
      Feb 3.